Revolution Medicines reported a survival benefit from a Phase III trial of daraxonrasib (RMC-6236), an investigational RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the RASolute 302 study, daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with standard cytotoxic chemotherapy. The company said the benefit was reflected in both progression-free and overall survival analyses, with the primary endpoints focusing on patients with RAS G12 mutations. Revolution plans to use the dataset for an FDA approval application, though timing was not specified in the briefing. The readout intensifies competition in precision oncology by pushing RAS-targeting into a clinically validated survival narrative for a disease with limited options. It also sets up a fast-moving evidence trajectory for next regulatory milestones and potential label expansion discussions.